University of Washington ACTU Seeks Participants for Two New Studies
Latest HIV/AIDS Clinical Trials
Open-label, Dose-escalation, Dideoxynucleoside-Associated Distal Symmetric Peripheral Neuropathy Pilot Study
Purpose: to see if taking acetyl-L-carnitine (ALC), an investigational substance, reduces neuropathy (numbness, pain, or tingling in legs and feet) in people who are taking anti-HIV drugs ddC, or ddI or d4T.
Length: 24 weeks
Reimbursement: exams, acetyl-L-carnitine, and lab tests given at no cost. Reimbursement of $20 per visit plus $50 for each visit when skin biopsies are done.
Contact: Alyssa Spingola or Lori Cray at (206) 731-3184 (firstname.lastname@example.org)
Crossover trial of valganciclovir in persons with HIV-1 infection and HIV and CMV co-shedding in semen
Purpose: to evaluate the effectiveness of oral valganciclovir in decreasing the shedding of HIV in semen.
Length: 12 weeks after entry
Reimbursement: Semen samples are reimbursed at the following rates: $15 for screening samples, $25 for each of the three samples at weeks 2-4, and $40 for each of the samples at weeks 8, 10, 11, and 12.
Contact: Leslie Deutsch (206) 543-8299 (email@example.com)
This article was provided by Seattle Treatment Education Project. It is a part of the publication STEP Perspective.